Search CYRX
Cryoport, Inc.
NasdaqCM · CIK 1124524
Last close17.43
Daily change+0.07 (0.40%)
10 Years gain+780.30%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CYRX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
40.3Momentum
100.0Acceleration
100.0Confidence
86.0Annual Revenue16
Quarterly Revenue74
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth6.6 / 25
Quality11.0 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics6.3 / 10
Forward Indicators1.4 / 5
Signals
Gross margin expansionGross margin improved by 2.8908 percentage points.
Operating leverageOperating margin improved by 53.224 percentage points.
ROIC expansionROIC improved by 56.1045 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM19.25%OK
Revenue CAGR 3Y-9.45%OK
Gross Margin46.9%OK
Operating Margin-21.04%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-24.92%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.99%OK
SBC / Revenue5.02%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $176.18M | $83.05M | -$36.81M | -$8.58M | -$25.02M | 47.14% | -20.89% | -14.2% | -23.96% | 50.07M |
| 2025 FY Dec 31, 2024 | $156.77M | $69.66M | -$121.67M | -$16.32M | -$33.58M | 44.43% | -77.61% | -21.42% | -98.72% | 49.35M |
| 2025 FY Dec 31, 2023 | $168.66M | $75.33M | -$100.54M | -$757,000.00 | -$39.54M | 44.67% | -59.61% | -23.44% | -190.7% | 48.74M |
| 2024 FY Dec 31, 2022 | $237.28M | $103.87M | -$31.90M | -$1.85M | -$23.96M | 43.78% | -13.45% | -10.1% | -95.28% | 48.99M |
| 2023 FY Dec 31, 2021 | $222.61M | $96.58M | -$17.83M | $8.13M | -$15.76M | 43.38% | -8.01% | -7.08% | -9.32% | 45.93M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $186.46M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-092107, 0001104659-25-107640 |
| Revenue Growth TTM | 19.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-092107, 0001104659-25-107640 |
| Revenue CAGR 3Y | -9.45% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-024180 |
| Revenue CAGR 5Y | 17.49% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-024180 |
| Gross Profit CAGR 3Y | -7.18% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-024180 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-092107, 0001104659-25-107640 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 46.9% | Gross Profit / Revenue | OK | 0001104659-26-092107, 0001104659-25-107640 |
| Operating Margin | -21.04% | Operating Income / Revenue | OK | 0001104659-26-092107, 0001104659-25-107640 |
| ROIC | -24.92% | NOPAT / Average Invested Capital | OK | 0001104659-26-092107, 0001104659-25-107640 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-092107 |
| Current Ratio | 2.08x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 5.02% | SBC / Revenue | OK | 0001104659-26-092107, 0001104659-25-107640 |
| Revenue per Diluted Share | $3.70 | Revenue / Diluted Shares | OK | 0001104659-26-092107, 0001104659-25-107640 |